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Abstract
Background:  Temporomandibular joint (TMJ) arthritis in children causes alterations in
craniomandibular growth. This abnormal growth may be prevented by an early anti-inflammatory
intervention. We have previously shown that intra-articular (IA) corticosteroid reduces TMJ
inflammation, but causes concurrent mandibular growth inhibition in young rabbits. Blockage of
TNF-α has already proven its efficacy in children with juvenile idiopathic arthritis not responding
to standard therapy. In this paper we evaluate the effect of IA etanercept compared to
subcutaneous etanercept in antigen-induced TMJ-arthritis in rabbits on histological changes using
histomorphometry and stereology. This article presents the data and discussion on the anti-
inflammatory effects of systemic and IA etanercept. In Part II the data on the effects of systemic and
IA etanercept on facial growth are presented.
Methods: Forty-two rabbits (10 weeks old) pre-sensitized with ovalbumin and locally induced
inflammation in the temporomandibular joints were divided into three groups: a placebo group
receiving IA saline injections in both joints one week after arthritis induction (n = 14), an IA
etanercept group receiving 0.1 mg/kg etanercept per joint one week after arthritis induction (n =
14) and a systemic etanercept group receiving 0.8 mg/kg etanercept weekly throughout the 12-
week study (n = 14). Arthritis was maintained by giving four inductions three weeks apart.
Additional IA saline or etanercept injections were also given one week after the re-inductions.
Histomorphometric and unbiased stereological methods (optical fractionator) were used to assess
and estimate the inflammation in the joints.
Results: The histomorphometry showed synovial proliferation in all groups. The plasma cell count
obtained by the optical fractionator was significantly reduced when treating with systemic
etanercept but not with IA etanercept. Semi-quantitative assessments of synovial proliferation and
subsynovial inflammation also showed reduced inflammation in the systemic etanercept group.
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However, the thickness of the synovial lining and volume of the subsynovial connective tissue
showed no differences between the groups.
Conclusion: An anti-inflammatory effect of systemic etanercept on the synovial tissues in the
temporomandibular joint was shown. However, IA etanercept at the given dose had no significant
effect on the severity of chronic inflammation on the parameters here tested in ovalbumin antigen-
induced arthritis.
Background
In juvenile idiopathic arthritis (JIA) the temporomandib-
ular joints (TMJs) are affected in more than 60% of the
patients, depending on the examination method used [1-
3]. TMJ involvement can lead to serious mandibular
growth alterations [4-6] because of a unique intracapsular
localization of the mandibular growth zone in the condy-
lar cartilage [7]. The use of intra-articular (IA) corticoster-
oids in the TMJ shows a favourable response in more than
50% by improving jaw movement and reducing pain [8].
However, the clinical long-term effects on growth of IA
corticosteroid therapy in juvenile TMJs are unknown. In
experimental TMJ arthritis we demonstrated that IA corti-
costeroid reduced inflammation but accentuated mandib-
ular growth disturbances [9-11]. Therefore a search for
alternative local anti-inflammatory treatment is war-
ranted.
The efficacy and safety of etanercept, a soluble tumor
necrosis factor (TNF)-α receptor fusion protein, has been
proven in a randomized controlled withdrawal-study in
children with severe polyarticular JIA [12,13]. In a small
clinical trial, administration of IA etanercept and IA corti-
costeroid shows comparable results in knee joints of rheu-
matoid arthritis patients [14]. The effects in this study
were measured using questionnaires and ultrasonogra-
phy. To our knowledge no data exist on histology in IA
etanercept. The use of IA etanercept is a promising candi-
date of local inflammation control in the TMJs, since no
side effects are expected in reducing the mandibular
growth.
In this study we investigated the effect of IA and systemic
administration of etanercept in ovalbumin antigen-
induced arthritis in the TMJ in young growing rabbits. The
effects on inflammation control will be discussed in the
present article and the aspects on mandibular growth will
be discussed in Part II: Mandibular growth [15].
Materials and methods
Forty-two female 10-week-old New Zealand white rabbits
(Oryctolagus cuniculus) were used. The rabbits were housed
at the animal facilities at Aarhus University, Denmark,
and had constant access to food and water. The animal-
welfare was supervised daily by the staff at the housing-
facilities. All procedures in this study were approved by
the Danish ethical committee for experimental animal
research.
The study design is shown in figure 1. All rabbits were sen-
sitized to ovalbumin using the method described by
Kapila [16], using 1 ml of ovalbumin (1 mg/ml) (Sigma
Chemicals, Steinheim, Germany) dissolved in physiolog-
ical saline and Freund's complete adjuvant® (IFA; Sigma
Chemicals, St. Louis, MO, USA). The procedure was
repeated two weeks later using Freund's incomplete adju-
vant®. All animals were tested for sensitivity one week after
by subcutaneous injection of 1 ml (1 mg/ml) ovalbumin
on a shaved spot (3 × 3 cm) on the back. Injection-site
inspection was done twelve hours later for signs of local
inflammation. An animal was considered sensitized if the
erythema was more than 1 × 1 cm, and the induration was
more than 0.5 × 0.5 cm.
Arthritis was induced in both TMJs one week after sensita-
tion by an IA injection with sterile filtered 0.1 ml ovalbu-
min (10 mg/ml) dissolved in physiological saline.
Arthritis was induced a total of four times, with 3-week
intervals in all animals. At the fourth arthritis induction
the ovalbumin dosage was reduced to 5 mg/ml because of
anaphylactic reactions at the 10 mg/ml dose. All IA injec-
tions in this study were done under anesthesia with 16 mg
ketamine, 0.8 mg xylazine and 0.17 mg acepromazine
given subcutaneously. The IA injections were done as
described by Kapila [16]. The mandible was manipulated
under general anesthesia and the condylar head was easily
palpated. When inside the lower joint chamber the injec-
tion is done slowly.
Animals were randomly assigned to receive either IA
saline (2 × 0.1 ml), IA etanercept (Enbrel®, Wyeth Pharma-
ceuticals Inc., Collegeville, PA, USA) bilaterally (2 × 0.1
mg/kg) or systemic etanercept (0.8 mg/kg) treatment.
The etanercept dose is calculated as follows:
IA saline or IA etanercept were administered one week
after every arthritis induction. We administered etanercept
systemically in the last group once weekly beginning one
Desired concentration
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week after the first arthritis induction. A total of ten ani-
mals died before study completion because of anaphylac-
tic shock against the ovalbumin at the 10 mg/ml dose,
which prompted dose reduction as mentioned.
Four days after the last treatment, the animals were euth-
anized for retrieval of histological samples using intrave-
nous pentobarbital (200 mg/ml).
Histological samples
One randomly chosen TMJ from each animal was
retrieved en bloc and placed in 70% ethanol. Dehydration
was done in 96% ethanol, 99% ethanol and equal
amounts of ethanol and acetone for four days.
A vertical axis perpendicular to the condylar cartilage was
defined. The joints were embedded in methylmethacr-
ylate (MMA, Merck KgaA, Darmstadt, Germany) with the
condylar cartilage parallel to the table. Before sectioning,
the joints were given a systematic randomly rotation
around the vertical axis. The sectioning was performed on
a microtome (Reichert-Jung Polycut E, Heidelberg, Ger-
many) parallel to the vertical axis using heavy-duty knives
(Leica Microsystems GmbH, Wetzlar, Germany), and sec-
tioning of the entire condyle was initiated when condylar
cartilage was recognized and continued throughout the
condyle resulting in five to eleven sampling levels. Sec-
tions were sampled in a systematic and uniformly random
manner in cycles of four consecutive 25 μm sections fol-
lowed by four consecutive 6.5 μm sections separated by
751 μm (25 × 4 + 6.5 × 4 + 25 × 25 μm). The 6.5 μm sec-
tions were placed on gelatine-coated slides and stained
with Goldner-Trichrome. The 25 μm sections were stained
floating with toluidin-blue and mounted on slides.
Flow chart of the study design Figure 1
Flow chart of the study design. Induction of arthritis was performed four times with three weeks intervals in all three 
groups. Number of animals lost during the study is shown with a †.
Rabbits n=42
Pre-sensitization, age 10  14 weeks
Randomization
IA
Saline
n=14
IA
etanercept
n=14
Systemic
etanercept
n=14
Induction of arthritis bilaterally in the TMJs
I.a. saline in 
TMJs
Systemic 
etanercept
I.a. etanercept
in TMJs
T2: Second head CT-scan session and euthanization, age 26 weeks 
5† 4† 1† + 1 outlier
Repeated 
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Weekly from
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The microtome was calibrated to verify the exact distance
between the sections. The microtome advance was 23.9
μm when the microtome was set to cut 25 μm thick sec-
tions [17]. All sections were evaluated by a blinded
observer.
Conventional histomorphometry
A central section from each joint was evaluated by conven-
tional histomorphometry. The parameters of interest
were: fractional surface, synovial lining thickness, semi-
quantitative (S-Q) scoring of inflammation in the sub-
synovial connective tissue (SSCT), and synovial prolifera-
tion. The SSCT is defined as the connective tissue between
the synovial lining and the mandibular bone in the lower
joint chamber in the TMJ. The lower border is an artificial
line perpendicular from the lower synovial fold to the
condylar bone and the upper border is the condylar carti-
lage. This area is easily recognized in the microscope (Fig-
ure 2).
The fractional surface is the percentage of normal synovial
lining. The fractional surface measurements were done in
an Olympus BX 51 microscope (magnification 200×) by a
single observer and an Olympus standard line-grid
(Olympus Denmark, Ballerup, Denmark). We counted
the intersections with normal synovial lining, hyperplas-
tic synovial lining and villous hyperplasia in the lower
joint-chamber. A mean of 138 intersections were counted
in each joint. Both hyperplastic synovial lining and villous
hyperplasia are considered pathological features, and the
statistical evaluation was therefore done on the fraction of
normal synovial lining.
Synovial thickness was measured by orthogonal intersec-
tions using the computer program SigmaScan Pro (Sig-
maScan Pro 4.03, Image Analysis, SPSS Inc., Chicago, IL,
USA). An attached digitizer and the Olympus standard
line grid was randomly rotated over the synovial lining
(magnification 200×). For each section 90–200 distances
were measured on one section. A mean value per section
(i.e. joint) was calculated, and this was multiplied by π/4
for correction of the oblique cutting phenomenon [18].
An experienced histologist scored the inflammation
degree in the SSCT by plasma cell presence blindedly. The
degree of inflammation was given a score from 0 to 4.
Scoring criteria: 0 = no plasma cells; 1 = few, scattered; 2 =
clearly present; 3 = multiple plasma cells organized in
bands; 4 = massive presence of plasma cells. Synovial pro-
liferation was scored accordingly from 0 to 4. Scoring cri-
teria: 0 = none; 1 = small areas with synovial proliferation;
2 = large areas with synovial proliferation; 3 = invasion
into the joint cavity by synovial proliferation; 4 = joint
cavity totally occupied by synovial proliferation. A score
was made of both the inner and outer synovial linings and
the combined score was divided by two.
Stereological method application
We used Cavalieri's unbiased volume estimator [19] on
the 6.5 μm sections to estimate the volume of the SSCT.
Point counting was only done in sections where synovial
cells could be defined. The area was calculated using ster-
eology software (CAST version 2, Visiopharm, Horsholm,
Denmark) that projected an unbiased counting grid on
the microscope image. A total magnification of 102× was
used and the area per point was 7500 μm2.
By applying stereological methods 3D information can be
obtained from correctly sampled 2D sections. This ena-
bles an accurate, unbiased quantification. The optical frac-
tionator was used for plasma cell counting in the SSCT on
the 25 μm sections [17,20]. By using the optical fraction-
ator, an unbiased estimate of the exact number of plasma
cells in the SSCT can be calculated, producing an estimate
of the severity of the chronic inflammation [21]. When
a: The subsynovial connective tissue (SSCT), b: upper limit of  SSCT, c: lower limit of SSCT, d: lower joint chamber, e: con- dylar bone, f: condylar cartilage, g: discus articularis (Gold- ner-trichrome) Figure 2
a: The subsynovial connective tissue (SSCT), b: upper 
limit of SSCT, c: lower limit of SSCT, d: lower joint 
chamber, e: condylar bone, f: condylar cartilage, g: 
discus articularis (Goldner-trichrome). From [9].Pediatric Rheumatology 2009, 7:5 http://www.ped-rheum.com/content/7/1/5
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using the optical fractionator with varying height sam-
pling fraction the local changes in height (shrinkage) of
the sections is taken into consideration [17].
The sections were viewed in an Olympus BX 50 micro-
scope equipped with a Heindenhain VRZ 401 microcater.
The microscope was mounted with a microscope stage
and a 3 CCD video camera connected to a computer. The
stereology software superimposed a 2D-unbiased count-
ing frame on the microscope image using a frame grabber
(Flashpoint 3D PRO, Image Processing Solution Inc.,
North Reading, MA, USA). Sections were studied in a total
magnification of 1540. Fields of view were sampled in a
systematic and uniformly random manner with X- and Y-
steps of 100 μm. The section height was measured uni-
formly in each section. A disector height of 15 μm was
used with an upper and lower exclusion level of 5 μm
each. In each field of view an unbiased counting frame
with the area of 3440 μm2 was superimposed on the
screen (Figure 3).
Statistics
To compare inter-group differences on continuing data
one-way analyses of variance tests were applied. Because
of a value of zero in the plasma cell counting, the data
were transformed to log(x+2), which also makes the data
normally distributed.
In the volume and number estimates, the variance of the
method was calculated as the coefficient of error (CE).
[21]. The coefficient of variation was calculated for the
histomorphometric measurements.
Differences between the groups were tested using Kruskal-
Wallis test and the two-sample Wilcoxon rank-sum
(Mann-Whitney) test for intergroup differences the semi-
quantitative scoring.
The statistics program Stata (Intercooled Stata 8.2, Stata-
Corp, College Station, TX, USA) was used. In all calcula-
tions a p <0.05 was considered significant.
Results
Thirty-two animals were available for histological investi-
gation after completion of the study. Ten animals were
lost due to the antigen-induced anaphylactic reaction.
Additionally, one animal from the systemic etanercept
group was excluded from the calculations as an outlier
because of a very high number of plasma cells in the SSCT
of more than 3 standard deviations above the second
highest. The high cellular count may be explained by an
intra-articular infection. However, neither neutrophils
nor bacteria were observed in the SSCT. Only animals
completing the entire study were used in the statistical
evaluation.
Data from the histomorphometry are shown in Figure 4.
Neither the fractional surface nor the thickness of the syn-
ovial lining changed after treatment with either IA or sub-
cutaneous etanercept.
The semi-quantitative scoring of inflammation in the
joint revealed that the systemic etanercept group had sig-
nificantly lower scores (p = 0.009) using an ANOVA test.
When t-tests were done they showed significant differ-
ences to the saline (p = 0.013) and the IA etanercept group
(p = 0.0017), respectively (Figure 5a). Figure 5b shows the
synovial proliferation scores. The systemic etanercept
group scores lowest with a p = 0.0025 against the saline
group and p = 0.0061 against the IA etanercept group.
No differences in volume of the SSCT were seen between
the groups (Figure 6a). The number of plasma cells in the
SSCT was significantly lower in the systemic etanercept
group compared to both the placebo and IA etanercept
groups with an ANOVA test result of p = 0.03 and t-tests
of p = 0.04 between the groups, respectively (Figure 6b).
Intra-observer variance
Conventional histological measurements: The coefficient
of variation was 0.042. Cell counting: The coefficient of
variation was 0.12. This is an acceptable value because of
the relatively few and scattered cells in the sections [22].
Typical band of plasma cells seen in the SSCT Figure 3
Typical band of plasma cells seen in the SSCT. An 
unbiased counting frame is projected on the section in the 
CAST 2 computer program; counting is done inside this 
frame. The criteria for identification of plasma cells were: a 
round nucleus, typical chromatine staining, and sparse cyto-
plasmatic staining. (Toluidin Blue, magnification: ×1540)Pediatric Rheumatology 2009, 7:5 http://www.ped-rheum.com/content/7/1/5
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Histomorphometric results Figure 4
Histomorphometric results. The dotted lines are the 95% confidence intervals. a: Fractional surface measurements. No 
statistical differences are seen between the groups. b: Synovial lining thickness. No statistical differences are seen between the 
groups.
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Semi-quantitative scores Figure 5
Semi-quantitative scores. a: S-Q scores of inflammation. Scoring criteria: 0 = no plasma cells; 1 = few, scattered; 2 = clearly 
present; 3 = multiple plasma cells organized in bands; 4 = massive presence of plasma cells. b: S-Q scores of synovial prolifera-
tion. Scoring criteria: 0 = none; 1 = small areas with synovial proliferation; 2 = large areas with synovial proliferation; 3 = inva-
sion into the joint cavity by synovial proliferation; 4 = joint cavity totally occupied by synovial proliferation. A score was made 
of both the inner and outer synovial linings and the combined score was divided by two. ¤: p < 0.01, *: p < 0.05.
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Stereological estimates Figure 6
Stereological estimates. a: The volume of the SSCT. Dotted lines indicate the 95% confidence intervals. No significant dif-
ferences are seen between the groups. b: The number of plasma cells in the SSCT estimated by the optical fractionator. Dot-
ted lines indicate the 95% confidence intervals. *: p < 0.05.
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Stereology: The CE(N) value was 0.053. The coefficient of
error for cell counting was only calculated when the
number of cells > 10,000 due to the low number and scat-
tered positions of the cells in the sections [23]. CE(Pi)
value of the Cavalieri estimator was 0.03.
Discussion
Inflammation in the TMJs in young rabbits was induced
and maintained for 12 weeks by a modified method orig-
inally described by Kapila et al. [16]. The model causes
inflammatory changes in the TMJ and contains both an
acute and a chronic stage predominated by mononuclear
cells [24,25], which is characteristic of the chronic inflam-
mation in patients with JIA [26] or rheumatoid arthritis
[27]. Thus, the histological features of this model resem-
ble the conditions seen in both rheumatoid arthritis and
JIA. The ovalbumin-induced arthritis has been thoroughly
tested and used for more than 40 years, but as with other
experimental models they rarely each reflect the full extent
of the complex, multi-faceted inflammatory process seen
in human autoimmune disease [28,29]. One must there-
fore always be careful when extrapolating data from ani-
mal studies to human studies.
TNF-α contributes to joint damage by its diverse actions
on proinflammatory cells and cytokines including the
receptor activator for nuclear factor-κB ligand (RANKL)
pathway [30]. TNF-α is elevated in both serum and syno-
vial fluid of children with juvenile idiopathic arthritis
[31]. Also, high levels of TNF-α present in synovial fluid
from the TMJ are related to increased TMJ pain experience
in rheumatoid arthritis patients [32]. Blocking TNF-α by
using subcutaneous etanercept has proven its efficacy and
safety for the treatment of polyarticular JIA [12,13]. There-
fore, intra-articular blockade of TNF-α could be a possible
therapy for patients with arthritis in the TMJ.
Intra-articular corticosteroids improves jaw movement
and reduces symptoms in arthritic temporomandibular
joints in children with juvenile idiopathic arthritis [8,33].
However, the long-term effects of repeated IA corticoster-
oids on the mandibular growth are still unknown. In pre-
vious studies we have examined IA corticosteroids in
antigen-induced TMJ arthritis in rabbits. Although reduc-
ing TMJ inflammation, IA corticosteroids aggravates the
arthritis-induced inhibition of the mandibular growth [9-
11].
The systemically administered etanercept was given once
weekly (0.8 mg/kg), which is equivalent to the human
dose per week given for the treatment of JIA [34,35]. The
etanercept dose given intra-articularly (0.1 mg/kg per
joint) was adjusted from a human study [36]. However,
no strict regimen for IA etanercept treatment exists [37],
and it can be argued that a higher dose should be given.
There are currently no studies describing the dose/
response of etanercept in rabbits. However, one study
reports that even high doses of etanercept is well tolerated
in healthy rabbit eyes where a dose of 1 mg/kg was admin-
istered [38]. This implies that higher doses also can be
given IA without toxic effects.
The model is essentially based on antigenic stimulation
by ovalbumin, which causes a systemic activation of the
immune system, proliferation of B-cells which are trans-
formed to plasma cells releasing antibodies in the syno-
vial tissues. Therefore, because systemic administration
with the highest accumulated dose has the greatest poten-
tial of suppressing the number of plasma cells systemi-
cally. Herein lays a bias in this model when comparing
systemic and local drug administration when evaluating
the number plasma cells. But what we can see is that local
administration of etanercept does not lower the number
of plasma cells compared to saline injections, meaning
that the IA etanercept does not lower the migration of
plasma cells to the inflamed joint. Using this model on
rabbit knees Idogawa and co-workers showed that the
TNF-production is high in the joint initially after ovalbu-
min injection and suggested that the inflammation is
TNF-driven. However, our IA etanercept injections were
performed seven days after ovalbumin injection where the
inflammation is chronic. This may explain why the effects
of the IA etanercept are low; we speculate that the effect on
initial inflammation can be higher than in chronic anti-
gen-induced arthritis.
The lack of effect of IA etanercept could also be explained
by its pharmacokinetics. The distribution of etanercept is
rapid, and it will therefore quickly diffuse out of the joint.
With a half-life between 70.8 and 96.4 hours in the organ-
ism it is possible that the IA concentration is rather low
after injection [35]. The time the etanercept stays within
the joint is not known. Also, the accumulated total dose
given is twelve times higher in the systemic group and in
combination with the rapid distribution of etanercept this
could be the reason for the lack of effect of IA etanercept.
Applying the etanercept intra-articularly too often could
result in scar-tissue formation and is not advised.
The results of the fractional surface measurements did not
reveal differences between the groups (Figure 4a). A large
percentage of the synovial lining is normal in all groups,
and a fractional surface measurement does not categorize
the villous hyperplasia or the hyperplastic synovium
according to degree, but merely as being present or not.
However, when given scores, clear statistical evidence of
lower scores in the systemic etanercept group compared to
the other groups was seen (Figure 5b). Therefore, systemic
etanercept has favorable immunomodulatory effects on
the synovial lining in this model.Pediatric Rheumatology 2009, 7:5 http://www.ped-rheum.com/content/7/1/5
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The thickness of the synovial lining was no different
between the groups (Figure 4b). This result was also found
in our previous study using IA corticosteroid [9].
Semi-quantitative scoring of the inflammation in the
SSCT revealed reduced inflammation in the systemic
etanercept group. S-Q scores (Figure 5a) and estimation of
the number of plasma cells in the SSCT (Figure 6b) both
indicate that the chronic inflammation is effectively
reduced in the rabbit.
No difference between the saline and IA etanercept groups
was present, neither in scoring of the synovial lining nor
the SSCT. Previously, we have found that IA saline injec-
tions did not cause inflammation nor accumulation of
plasma cells in the non-pathological SSCT [9]. Therefore,
because the S-Q scores and synovial lining measurements
were similar for the IA saline and IA etanercept groups, we
conclude that IA etanercept has no significant effect on the
parameters studied in this study of chronic inflammation.
Conclusion
Although numerous cytokines are involved in the patho-
genesis of JIA [31], TNF-α-blockade by the use of etaner-
cept alone had significant anti-inflammatory effects on
experimentally ovalbumin-induced TMJ arthritis. How-
ever, in the parameters used in this study IA etanercept
(0.1 mg/kg) had no significant effects on the severity of
inflammation in ovalbumin antigen-induced arthritis and
was inferior to systemic administration of etanercept in
management of chronic inflammation.
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